Matches in SemOpenAlex for { <https://semopenalex.org/work/W2774788400> ?p ?o ?g. }
- W2774788400 endingPage "15" @default.
- W2774788400 startingPage "4" @default.
- W2774788400 abstract "This 48-week, randomized, placebo-controlled phase 3 study (DMD114044; NCT01254019) evaluated efficacy and safety of subcutaneous drisapersen 6 mg/kg/week in 186 ambulant boys aged ≥5 years, with Duchenne muscular dystrophy (DMD) resulting from an exon 51 skipping amenable mutation. Drisapersen was generally well tolerated, with injection-site reactions and renal events as most commonly reported adverse events. A nonsignificant treatment difference (P = 0.415) in the change from baseline in six-minute walk distance (6MWD; primary efficacy endpoint) of 10.3 meters in favor of drisapersen was observed at week 48. Key secondary efficacy endpoints (North Star Ambulatory Assessment, 4-stair climb ascent velocity, and 10-meter walk/run velocity) gave consistent findings. Lack of statistical significance was thought to be largely due to greater data variability and subgroup heterogeneity. The increased standard deviation alone, due to less stringent inclusion/exclusion criteria, reduced the statistical power from pre-specified 90% to actual 53%. Therefore, a post-hoc analysis was performed in 80 subjects with a baseline 6MWD 300-400 meters and ability to rise from floor. A statistically significant improvement in 6MWD of 35.4 meters (P = 0.039) in favor of drisapersen was observed in this subpopulation. Results suggest that drisapersen could have benefit in a less impaired population of DMD subjects." @default.
- W2774788400 created "2017-12-22" @default.
- W2774788400 creator A5001131087 @default.
- W2774788400 creator A5003290672 @default.
- W2774788400 creator A5004764910 @default.
- W2774788400 creator A5006221593 @default.
- W2774788400 creator A5006535710 @default.
- W2774788400 creator A5006695139 @default.
- W2774788400 creator A5006862511 @default.
- W2774788400 creator A5006904488 @default.
- W2774788400 creator A5011012573 @default.
- W2774788400 creator A5015604583 @default.
- W2774788400 creator A5016478750 @default.
- W2774788400 creator A5020133024 @default.
- W2774788400 creator A5020462584 @default.
- W2774788400 creator A5023165371 @default.
- W2774788400 creator A5025250099 @default.
- W2774788400 creator A5026597828 @default.
- W2774788400 creator A5027810336 @default.
- W2774788400 creator A5027963728 @default.
- W2774788400 creator A5029096985 @default.
- W2774788400 creator A5029477741 @default.
- W2774788400 creator A5030418260 @default.
- W2774788400 creator A5030692760 @default.
- W2774788400 creator A5031447300 @default.
- W2774788400 creator A5031960202 @default.
- W2774788400 creator A5032162324 @default.
- W2774788400 creator A5034869543 @default.
- W2774788400 creator A5038988072 @default.
- W2774788400 creator A5040386348 @default.
- W2774788400 creator A5040723911 @default.
- W2774788400 creator A5042269980 @default.
- W2774788400 creator A5042500656 @default.
- W2774788400 creator A5043572107 @default.
- W2774788400 creator A5043897574 @default.
- W2774788400 creator A5044404481 @default.
- W2774788400 creator A5045646843 @default.
- W2774788400 creator A5048193467 @default.
- W2774788400 creator A5050704861 @default.
- W2774788400 creator A5053684012 @default.
- W2774788400 creator A5054727366 @default.
- W2774788400 creator A5056012852 @default.
- W2774788400 creator A5056128184 @default.
- W2774788400 creator A5060787128 @default.
- W2774788400 creator A5063644213 @default.
- W2774788400 creator A5068294141 @default.
- W2774788400 creator A5068661720 @default.
- W2774788400 creator A5070193666 @default.
- W2774788400 creator A5070600479 @default.
- W2774788400 creator A5071163954 @default.
- W2774788400 creator A5074941933 @default.
- W2774788400 creator A5075955950 @default.
- W2774788400 creator A5077852694 @default.
- W2774788400 creator A5080269100 @default.
- W2774788400 creator A5081817483 @default.
- W2774788400 creator A5089564343 @default.
- W2774788400 creator A5089769676 @default.
- W2774788400 date "2018-01-01" @default.
- W2774788400 modified "2023-10-18" @default.
- W2774788400 title "A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy" @default.
- W2774788400 cites W1508659364 @default.
- W2774788400 cites W1519486737 @default.
- W2774788400 cites W1524530894 @default.
- W2774788400 cites W1533447420 @default.
- W2774788400 cites W1558196299 @default.
- W2774788400 cites W1771343264 @default.
- W2774788400 cites W1890633682 @default.
- W2774788400 cites W1951817210 @default.
- W2774788400 cites W1966161605 @default.
- W2774788400 cites W1966218392 @default.
- W2774788400 cites W1966981537 @default.
- W2774788400 cites W1975417324 @default.
- W2774788400 cites W1984372039 @default.
- W2774788400 cites W1985495937 @default.
- W2774788400 cites W1989951588 @default.
- W2774788400 cites W1997730532 @default.
- W2774788400 cites W1999113624 @default.
- W2774788400 cites W2000912972 @default.
- W2774788400 cites W2001407064 @default.
- W2774788400 cites W2005330089 @default.
- W2774788400 cites W2006777295 @default.
- W2774788400 cites W2009324880 @default.
- W2774788400 cites W2010757394 @default.
- W2774788400 cites W2012621742 @default.
- W2774788400 cites W2018862827 @default.
- W2774788400 cites W2019952853 @default.
- W2774788400 cites W2023967471 @default.
- W2774788400 cites W2025669016 @default.
- W2774788400 cites W2031634153 @default.
- W2774788400 cites W2035947437 @default.
- W2774788400 cites W2041052974 @default.
- W2774788400 cites W2045533831 @default.
- W2774788400 cites W2058459242 @default.
- W2774788400 cites W2065376245 @default.
- W2774788400 cites W2072832813 @default.
- W2774788400 cites W2102807861 @default.
- W2774788400 cites W2104142451 @default.
- W2774788400 cites W2108678383 @default.